Guidelines
Platelet Count Thrombocytopenia: The Most Common Cause of Bleeding Thrombocytosis Platelet Diameter and Morphology Qualitative Platelet Abnormalities Drugs with Anti-platelet Activity Platelet Aggregometry Platelet Concentrate Therapy Treating Uremic Platelet Dysfunction with Red Blood Cells Thrombotic Thrombocytopenic Purpura (TTP) and the vWF-Cleaving Protease (ADAMTS-13) Assay
Platelet Count Ranges and Thrombocytopenia
|
150-400,000/uL |
Platelet count reference interval; < 150,000 is thrombocytopenia |
|
50-150,000/uL |
Bleeding is unexpected, implies qualitative platelet disorder |
|
10-50,000/uL |
Bleeding may follow trauma, surgery, or dental extraction |
|
<10,000/uL |
Spontaneous bleeding may require therapy |
[top]
Thrombocytopenia: the most common cause of bleeding
Marrow hypoplasia: chemotherapy, drug sequelae, ethanol
Immune-mediated platelet consumption: acute and chronic autoimmune thrombocytopenic purpura, drug-induced immune thrombocytopenia, neonatal alloimmune thrombocytopenia, post-transfusion purpura
Non-immune mediated platelet consumption: thrombotic thrombocytopenic purpura (TTP), hemolytic-uremic syndrome (HUS), disseminated intravascular coagulation (DIC), heparin-induced thrombocytopenia (HIT), type 2B VWD, and others.
[top]
Thrombocytosis: Count > 400,000/uL
- Reactive thrombocytosis: hemorrhage, surgery, iron deficiency anemia, inflammation - normal platelets - no bleeding risk
- Myeloproliferative disorders: essential thrombocythemia, chronic myelocytic leukemia, polycythemia vera - abnormal platelets may cause thrombosis or bleeding
[top]
Platelet Diameter and Morphology
|
2.5 mm diameter |
Average normal diameter |
|
4 mm diameter |
Large physiologic platelets may indicate increased turnover with shortened marrow release time |
|
>7 mm diameter |
Giant platelets imply myeloproliferative disorder, myelodysplastic syndrome, May-Hegglin anomaly |
|
Gray platelets |
Slightly enlarged gray platelets seen in Bernard-Soulier syndrome or alpha-granule deficiency (Gray platelet syndrome) |
|
Platelet clumps |
Clotting due to improper specimen management or agglutination due to EDTA-dependent antibody |
|
Platelet satellitism |
Artifact of EDTA-dependent antibody |
[top]
Qualitative Platelet Abnormalities
These disorders may be suspected after abnormal platelet aggregation results:
Congenital storage pool deficiency: dense granules
-
Normal platelet dense (d) granules store ADP, ATP, calcium, pyrophosphate, and serotonin, and release these during activation.
-
Hermansky-Pudlak and Chediak-Higashi syndromes are rare autosomal recessive disorders with oculocutaneous albinism.
-
Wiskott-Aldrich syndrome, an X-linked recessive disorder, is characterized by severe eczema.
-
All three have reduced dense granule distribution (diagnosed by electron microscopy) and moderate thrombocytopenia.
- Dense granule deficiency in non-albinos may be caused by an autosomal dominant inability to package the normal contents despite producing normal granules. Platelet counts are normal.
Congenital storage pool deficiency: a granules
- The a granules store coagulation factors, platelet-derived growth factor (PDGF) and platelet factor 4. They provide the granular appearance of platelets by light microscopy.
- Gray platelet syndrome is the absence of a granules; the platelets are large and gray. Patients experience thrombocytopenia and moderate life-long bleeding.
Acquired storage pool deficiency: MPD or MDS
- Platelets in myeloproliferative disorders and myelodysplastic syndromes have reduced a and d granules, abnormal membranes, and vary in size and count.
- Patients may have mild to moderate bleeding, although thrombosis is also a risk.
- Platelet aggregometry may be used to predict clinical bleeding.
Platelet receptor defects
Following is a table of platelet membrane receptor defects that may associate with mucocutaneous bleeding. These may be detected using platelet aggregometry.
|
Receptor |
Function |
Agonist |
Defect |
|
GP Ib/V/IX |
VWF binding |
Ristocetin |
Bernard-Soulier syndrome |
|
GP IIb/IIIa |
Fibrinogen and VWF binding |
ADP, collagen, epinephrine |
Glanzmann thrombasthenia |
|
GP Ia/IIa |
Collagen binding |
Collagen |
Unnamed mucocutaneous bleeding |
|
P2Y1 and P2Y12 |
ADP binding |
ADP |
|
Thromboxane A2 receptor |
Thromboxane A2 binding |
Arachidonic acid |
|
a-adrenergic receptor |
Epinephrine binding |
Epinephrine |
May/may not cause bleeding |
Metabolic pathway defects
Defects in cyclooxygenase and thromboxane synthetase result in decreased thromboxane A2 production and poor platelet secretion despite normal granule distribution. These are called platelet release or secretion defects. They resemble the effect of aspirin on cyclooxygenase, giving the name, "aspirin-like disorders." These are detected by a reduced aggregation response to arachidonic acid agonist.
Other acquired platelet response deficiencies
Multiple myeloma, cardiopulmonary bypass surgery, liver disease, and uremia may all be associated with reduced platelet function.
[top]
Drugs with Anti-Platelet Activity
Platelets are inhibited by many common drugs such as aspirin, NSAIDs, various antibiotics, herbs, garlic, and vitamin E (among many others). Specific platelet inhibitors include clopi-dogrel and ticlopidine which block the ADP receptors, and abciximab, eptifibatide and tirofiban which bind to the IIb/IIIa receptors. Complications of some of these drugs include drug-induced immune thrombocytopenia which can be severe.
[top]
Platelet Aggregometry
Platelet aggregometry is a functional test performed on whole blood or platelet-rich plasma. An agonist (platelet activator) is added to the suspension and a dynamic measure of platelet clumping is recorded. ATP release is simultaneously assayed using a luminescence marker.
Expected aggregation and secretion results for aspirin, release defect, membrane defect, or storage pool disorder using a variety of agonists
|
Agonist |
Aspirin or Release Defect |
Membrane Defect |
Storage Pool
Deficiency |
|
Thrombin |
Normal secretion and aggregation |
Normal secretion and aggregation |
Decreased secretion and aggregation |
|
Arachidonic acid |
Decreased secretion and aggregation |
Normal secretion and aggregation |
Decreased secretion and aggregation |
|
ADP, epinephrine, and collagen |
Decreased secretion and aggregation |
Decreased secretion and aggregation |
Decreased secretion and aggregation |
[top]
Platelet Concentrate Therapy
Two types of platelet components are used for platelet replacement:
-
"Platelets", also called random donor platelets, are pooled concentrates prepared from whole blood donations by centrifugation. Usually a pool consists of 6-8 units, for an adult dose of one unit/10 kg of body weight. Each random unit contains at least 5 x 1010 platelets.
-
"Platelets, pheresis", or single donor platelets, are prepared by apheresis of one donor and contain a minimum of 300,000,000 platelets.
Therapeutic platelet transfusions are given to treat bleeding due to defects in platelet production or platelet function. Transfusion of platelets is contraindicated for diseases involving thrombotic consumption of platelets, including thrombotic thrombocytopenic purpura (TTP), hemolytic uremic syndrome (HUS), and heparin-induced thrombocytopenia (HIT).
Platelet transfusions are not usually effective in immune-mediated thrombocytopenias, such as idiopathic thrombocytopenia purpura (ITP), although there may be some benefit in life-threatening situations.
Recommended triggers for the use of platelet concentrate:
|
10,000/uL |
Stable oncohematological recipient, lumbar puncture in stable pediatric leukemia, thrombocytopenia 2° to GPIIb/IIIa receptor inhibitors |
|
20,000/uL |
Bone marrow aspiration and biopsy |
|
20-40,000/uL |
Gastrointestinal endoscopy in cancer |
|
20-50,000/uL |
DIC, fiber-optic bronchoscopy in a bone marrow transplant recipient |
|
30,000/uL |
Neonatal alloimmune thrombocytopenia |
|
50,000/uL |
Major surgery in leukemia, thrombocytopenia secondary to massive transfusion, invasive procedure in cirrhosis |
|
50-60,000/uL |
Cardiopulmonary bypass |
|
50-100,000/uL |
Liver biopsy, non-bleeding premature infant, neurosurgery |
Ideally, the effectiveness of platelet transfusions will be confirmed by bleeding cessation. If there are no complicating factors affecting response, such as hemorrhage, fever, or splenomegaly, a single unit of random platelets should increase the recipient's platelet count by 5000-10,000/uL, and a unit of apheresis platelets should increase the count by 30,000-50,000/uL. Many multi-transfused patients do not show the expected increment after platelet transfusion. The most common method to determine if the recipient is refractory to platelets is to measure the platelet count within one hour post transfusion and calculate the corrected count increment (CCI):
CCI = (Posttransfusion PLT count – Pretransfusion PLT count) x body area (m2)
Number of platelets transfused (multiples of 1011)
A CCI above 7500/uL indicates an adequate response to platelet transfusion. A CCI below 7500/uL suggests immune-mediated clearance and are the basis for the procurement of crossmatched platelets for subsequent transfusions.
Uremic hemorrhage results from platelet abnormalities secondary to kidney failure. While platelet transfusions may be used, they are not very effective. Cryoprecipitate may be helpful but red blood cells are the treatment of choice, particularly if the patient is anemic. A target hematocrit of 30% has been shown to improve platelet function in uremic patients.
[top]
Thrombotic Thrombocytopenic Purpura (TTP) and the VWF-Cleaving Protease (ADAMTS-13) Assay
Thrombotic thrombocytopenic purpura (TTP) is caused by ultra-high molecular weight von Willebrand factor multimers, present when endothelial cell-secreted von Willebrand factor is not properly proteolysed by its cleaving protease (ADAMTS-13). Lack of enzyme activity is most commonly the consequence of an autoantibody in the acquired form of TTP. In rare patients, TTP is familial and due to absence of ADAMTS-13. Hemolytic-uremic syndrome (HUS) resembles TTP, however bacterial toxins trigger HUS and the von Willebrand factor cleaving protease level remains normal. Although measurement of the von Willebrand factor cleaving protease activity is helpful in the diagnosis of TTP, the assay is complex and the turnaround time is too long to wait prior to making the diagnosis and starting plasmapheresis. However, it is important to collect a blood sample in sodium citrate for testing of ADAMTS-13 activity and its inhibitor prior to starting the first plasma exchange. One of the current available assays is based on the ability of vWF to bind collagen and is available from the Blood Center of Wisconsin.
[top]
© Copyright by the University of Alabama at Birmingham
Top of Page
|